EGFR-IN-3 is primarily utilized in cancer research and drug development due to its ability to inhibit the epidermal growth factor receptor (EGFR). This receptor is often overactive in various types of cancers, including lung, colorectal, breast, and head and neck cancer. By targeting EGFR, EGFR-IN-3 helps in studying the pathways and mechanisms involved in tumor growth and proliferation. It is also used in preclinical studies to evaluate the efficacy of potential therapeutic agents designed to block EGFR signaling, which can lead to the suppression of cancer cell survival and metastasis. Additionally, EGFR-IN-3 serves as a valuable tool in understanding resistance mechanisms to EGFR-targeted therapies, aiding in the development of more effective treatment strategies.